Diagonal Bio’s platforms using an 8-parallel test format, show overall Accuracy of 99.6 %, Sensitivity of 100 %, and Specificity of 99.5 %.
Read moreDiagonal Bio AB (publ) (“Diagonal Bio” or the “Company”) today announces a strategic step to strengthen its sales and marketing efforts. The company has secured the commitment of Johan Källstrand, one of the company’s founders with extensive experience and knowledge within the company’s market areas. The agreement means that Diagonal Bio is supported by Källstrand’s long experience and deep knowledge to strengthen its go-to-market strategy.
Read moreNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Today, the 8[th] of April 2024, the subscription period in Diagonal Bio AB’s (“Diagonal Bio” or “the Company”) issue of units consisting of shares and consideration free warrants of series TO 1 (”TO 1”), with preferential right for the Company’s existing shareholders begins. The subscription period runs until the 22[nd] of April 2024. The issue volume initially amounts to a maximum of approximately SEK 32 million before transaction costs (the “Rights Issue”). Upon full subscription of the Rights Issue and full utilization of issued TO 1 at the highest subscription price, the Company may receive an additional approximately SEK 9.5 million before transaction costs. The Rights Issue is secured in writing by members of the board, management, existing shareholders, and external investors to a total of approximately 56.4 percent (corresponding to approximately SEK 18 million) through pre-subscription and guarantee commitments. A prospectus is available via the Company’s (www.diagonalbio.com), Sedermera Corporate Finance AB’s (www.sedermera.se) and Nordic Issuing AB’s (www.nordic-issuing.se) websites. The Company’s will today, the 8[th] of April 2024, present at an event with Financial Stockholm at Scandic Klara Hotell.
Read moreDiagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces the extension of its partnership with Hørsholm Veterinary Clinic following the successful completion of a three-month pilot study. The pilot study was focused on utilizing Diagonal Bio’s platform technology, LAMPlify®, for the detection of viral infections in horses. The successful results were validated by an independent external laboratory in Germany, underscoring the efficacy and reliability of the LAMPlify® analysis system.
Read moreNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Diagonal Bio AB (“Diagonal Bio” or the “Company”) announced on the 28[th] of February 2024 that the board, subject to approval by the extraordinary general meeting, resolved on a rights issue of units with preferential rights for the Company’s shareholders. The extraordinary general meeting was held on the 2[nd] of April 2024 and approved the board’s decision. The Financial Supervisory Authority has today, on the 3[rd] of April 2024, approved and registered the prospectus that Diagonal Bio prepared in connection with the rights issue. The prospectus is available on Diagonal Bio’s website (www.diagonalbio.com), Sedermera Corporate Finance AB’s website (www.sedermera.se) and the Financial Supervisory Authority’s website (www.fi.se).
Read more
